Clinical Trial

A Study to Observe the Long-term Safety of Odevixibat in Patients With Alagille Syndrome (ALGS) Who Are Receiving Ongoing Treatment

Recruiting
View on ClinicalTrials.gov →
Summary
This study will collect information from patients with ALGS who are using odevixibat in their daily lives. Odevixibat is a medication that helps patients with ALGS, a rare disease that affects the liver and causes itching. The main aim of this study is to observe the long-term, everyday safety of the drug odevixibat in patients with ALGS who are receiving ongoing treatment.
Protocol Amendment History 2 changes
critical Recruitment opened 2026-08-04
notable Trial sites expanded: 0 -> 14 locations 2026-08-04
Trial Details
NCT Number NCT07585097
Lead Sponsor Ipsen
Conditions Alagille Syndrome
Enrollment 30 participants
Start Date 2026-07-10
Primary Completion 2031-09-30 (estimated)
Study Completion 2031-09-30 (estimated)
Updated on ClinicalTrials.gov 2026-08-03